Protocol Ledger

NCT04533581 · Phase II · ACTIVE NOT RECRUITING

Study of ME-401 in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma (NHL)

Interventional Phase II clinical trial protocol NCT04533581 sponsored by Kyowa Kirin Co in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-09-17 Enrollment: 61 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04533581
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)61 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04533581
Protocol FieldVerified Registry Value
NCT IdentifierNCT04533581
Consolidated Lead SponsorKyowa Kirin Co
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment61 participants (ACTUAL)
Registered Start Date2020-09-17
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04533581
Hospital Research SiteLocationSite Profile
Hokkaido University HospitalSapporo, JapanOpen Hospital Dossier ->
Mie University HospitalTsu, JapanOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI